Abstract
INTRODUCTION
The optimal strategy for postoperative analgesia after video-assisted thoracoscopic surgery (VATS) lobectomy still remains undetermined [1] . In a previous observational study from our institution, acceptable postoperative analgesia after VATS lobectomy was achieved using a multimodal analgesic regimen of oral paracetamol, non-steroid anti-inflammatory drugs and gabapentin, supplemented by an intraoperative paravertebral nerve block and an intercostal catheter (ICC) [2] . Preoperative administration of glucocorticoids has been shown to reduce acute postoperative pain and opioid consumption and to enhance recovery after various surgical procedures [3] [4] [5] [6] [7] [8] but has not been assessed in VATS lobectomy. Consequently, we did a double-blinded randomized controlled trial to investigate the analgesic effect of 125 mg methylprednisolone (MP) administered preoperatively in patients undergoing VATS lobectomy. Secondarily, we assessed the effects on postoperative nausea, fatigue and sleep quality as well as potential side effects.
MATERIALS AND METHODS
The study was approved by the Regional Ethics Committees of the Capital Region, Denmark (reference: We included consenting patients > _18 years who underwent elective VATS lobectomy at the Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen University Hospital, Denmark. between 21 March 2013 and 23 September 2015. Exclusion criteria were inability to cooperate, inability to speak or understand Danish, no planned follow-up at Rigshospitalet, allergies to any used medicines, symptomatic gastric ulceration, New York Heart Association functional classification > _3, preoperative increased plasma creatinine, pharmacologically treated diabetes mellitus, abuse of medicine or alcohol (> _5 units/day), use of psychopharmacological agents, systemic steroids (except inhalations) and/or opioid agonists, neurological deficits affecting pain perception, previous ipsilateral pulmonary resection, pregnancy and/or breast feeding. Included patients were withdrawn if they were reoperated on within 72 h, had massive intrathoracic adherences, deviated from the standard postoperative analgesia, converted to thoracotomy and/or breached protocol rules. Patients who received the study medicine and had completed 48 h of postoperative registrations (with at least 3 timely independent scorings on the day of surgery) were included in the primary 'per-protocol' analysis, even if they were not available for follow-up. Screening for eligibility and for participant information was done by an investigator 1-3 days before surgery, allowing time before obtaining written consent.
Before the start of the study, 100 sealed opaque envelopes were prepared by persons with no relation to the study, based on a computer-generated randomization sequence (1:1 ratio, block size 20 and no stratification). An additional block of 20 envelopes was prepared later by the same procedure. Randomization envelopes and the study medicines were located away from the operating theatre. When the person was accepted in the study, the investigator phoned an intensive care unit nurse who opened the next envelope and prepared a 2-ml syringe with 125 mg MP or a 2-ml 0.9% saline (placebo group), depending on the enclosed information. The syringe was blinded by a plaster bandage and brought to the investigator who administered the medicine to the patient after induction of anaesthesia, but before the start of surgery. Patients, caregivers and investigators were blinded to group assignment.
Anaesthesia was administered intravenously using propofol, remifentanil and 10 mg of morphine administered about 30 min before the end of surgery. All patients had a left-sided, double-lumen endotracheal tube, 2 peripheral intravenous catheters and an arterial line. Pressure-controlled ventilation was used during one-lung ventilation. Patients were extubated in the operating room and observed in a specialized postanaesthesia care unit (PACU) until the next morning. Standard analgesia included paracetamol, ibuprofen and gabapentin, supplemented by a paravertebral nerve block and an ICC placed intraoperatively by the surgeon [2] , with morphine or a bolus of bupivacaine in the ICC for breakthrough pain. Oral analgesics were started before surgery and continued for at least 48 h, unless there were side effects ( Table 1 ). All VATS lobectomies were performed by experienced thoracic surgeons using a standardized 3-port technique, as previously described [9, 10] .
Preoperative and intraoperative information included demographic data, American Society of Anesthesiologists physical status classification, preoperative lung capacity (forced expiratory volume in 1 s), self-reported preoperative pain (yes/no), the reason for performing VATS lobectomy, duration of surgery and type of resection. Postoperative pain, nausea and sedation were scored by trained nurses every 3rd hour from arrival in the PACU until midnight on the day of surgery. On postoperative days (POD) 1 and 2, patients scored pain and nausea twice daily (08:00 and 20:00 h) according to instructions given by an investigator on the first postoperative morning. In addition, at 08:00, PODs 1-3, the patients scored their average fatigue during the last 24 h (on POD 1; since the end of surgery) and the quality of their sleep the previous night. Pain was scored on a numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain) during 4 predefined activities: at rest, after mobilization from supine to sitting position (without help), with both arms abducted at least 90 and when coughing. If a patient reported inability to sit, to abduct the arm or to cough because of pain, this was interpreted as the 'worst imaginable pain', whereas all other reasons were considered missing data. For sedation, we used an NRS of 0-4 (0: awake and alert, 1: reacts when spoken to, 2: reacts when touched, 3: reacts to strong physical stimulation and 4: unresponsive); for nausea, an NRS of 0-3 (0: no nausea, 1: light nausea, 2: severe nausea and 3: vomiting) and for fatigue and sleep quality, an NRS of 1-10 (0: no fatigue/best imaginable sleep, 10: 'exhausted'/no or worst imaginable sleep). Other postoperative data included use of analgesics and antiemetics, blood glucose levels on the day of surgery, POD of removal of the chest tube and ICC and POD of discharge. Follow-up on complications was obtained in the postoperative clinic after 2 to 3 weeks and by telephone after 12 weeks.
Our primary outcome was to track pain in the first 48 h postoperatively. Secondary outcomes included sedation and blood glucose levels on the day of surgery, use of supplemental analgesics, postoperative nausea, fatigue and sleep quality and the incidence of wound healing problems and/or postoperative infections within 12 weeks after surgery.
Statistical analysis
In a previous observational study of a similar population, the mean area under the curve for pain on an NRS 0-10 was 3.2 (SD 1.6) within the first 48 h after VATS lobectomy [2] . We aimed to detect a pain reduction of 30% (about 1.0 point on the NRS 0-10) with 80% power and a 0.05 significance level (2-sided), yielding a need for a minimum of 84 patients (42 in each group). Expecting a dropout rate of 5-10%, we initially included 100 patients, but as dropouts and exclusions reached about 20% (Fig. 1) , we included an additional 20 patients during the study period.
All analyses were performed 'per protocol' by the primary investigator (L.S.B.) after inclusion of the 120 patients and before unblinding of data, using the SAS statistical software version 9.4 (SAS Institute, Inc., Cary, NC, USA). Normally distributed continuous data, assessed by the Kolmogorov-Smirnov goodness-of-fit test, were reported as means with SD and compared between groups using the unpaired t-test, whereas non-normally distributed data were reported as medians with interquartile range and compared between groups by the Mann-Whitney U-test. The NRS data were considered continuous data and for measurements repeated over time, area under the curves were calculated. Categorical data are given as counts with group percentages and compared between groups by the Fisher exact test. Because of the different methods of data collection and the different time intervals between scorings, data from the day of surgery and from POD 1 and onward were analysed separately. Pain scores were analysed primarily for those patients with complete data, but because 28 patients (about 30%) had one or more missing scores during the day of surgery, we performed a supplemental multiple imputation model analysis of this period, using age, gender, duration of surgery and the previous pain score as explanatory variables.
RESULTS
Of the 422 patients assessed for eligibility, 120 (28%) patients were included. One (1%) patient withdrew informed consent and 23 (19%) patients were withdrawn by the investigators, leaving 96 (80%) patients for the final analysis; 49 were assigned to the MP group and 47 to the placebo group (Fig. 1) . The median age of the 302 non-included patients was 69 (interquartile range 62-75) years; 54% were females. Thirteen of the included patients (4 from the MP group and 9 from the placebo group) had missing data on the day of surgery because they arrived in the PACU after 15:00 h and were therefore not scored after 9 h. Furthermore, 9 patients were unable to carry out one or more activities (mobilization, arm spreading and/or coughing) at the time of arrival in the PACU. Data missing from PODs 1 and 2 were generally fewer and showed no time-specific distributions.
Baseline characteristics and perioperative data are presented in Tables 2 and 3 , and with the exception of gender, these showed an acceptable balance between the groups. Median pain scores were lower on the day of surgery in the MP group for all activities but did not reach statistical significance for arm abduction and coughing (Table 4 ). In the multiple imputation analysis, pain scores were insignificantly reduced during all activities (P = 0.08, 0.07, 0.18 and 0.22 for rest, arm abduction, mobilization and coughing, respectively). Differences in pain scores from PODs 1 and 2 were generally smaller than on the day of surgery, without differences in the use of supplemental analgesics at any time during the postoperative period (Tables 4 and 5 ). By analysing the pain data for male and females separately, we found no systematical difference between genders, despite a weak trend towards higher pain scores in females than males from the MP group that was not present in the placebo group (Table 4) . Considering all non-imputed pain scores, 24 of 49 (49%) patients in the MP group and 28 of 47 (60%) patients in the placebo group reported NRS > _5 at one or more occasions on the day of surgery (P = 0.31). At PODs 1 and 2, these proportions were 22 of 49 (45%) patients and 29 of 47 (62%) patients for the MP group and the placebo group, respectively (P = 0.11).
Patients in the MP group had less nausea and fatigue but significantly higher blood glucose levels on the day of surgery (Table 5) . No other secondary outcome showed a statistically significant difference between groups ( Table 5 ).
The incidence of wound healing problems 2-3 weeks postoperatively was 5 of 49 (10%) patients in the MP group and 8 of 47 (17%) patients in the placebo group (P = 0.15). In 3 cases, wound infection was suspected but not proved (2 in MP group and 1 in placebo group). Twelve weeks after surgery, 2 patients from each group found their wounds insufficiently healed and 1 patient from the MP group had received antibiotics for a suspected wound infection. Non-surgical site infections were noted in 19 patients during the 12-week follow-up period, with no significant differences between groups in the type or incidence of these infections.
During the study period, we registered 34 adverse events, of which 17 were classified as 'maybe related to study medicine'. These were 2 cases of new onset postoperative atrial fibrillation (1 from each group), 1 case of an increased frequency of a preexisting atrial fibrillation (MP group), 1 case of transient postoperative hypotension (placebo group), 3 cases of stomach pain (1 from the MP group and 2 from the placebo group), 1 case of transient vision disturbance (placebo group), 2 cases of confusion (both placebo group), 1 case of increased serum creatinine level (MP group) and 6 cases who needed insulin because of blood glucose levels >252 mg/dl on the day of surgery (all in the MP group). MP did not affect postoperative chest tube duration or length of stay (Table 3) .
DISCUSSION
This study illustrated a moderate additive analgesic effect of a single, preoperative dose of 125 mg MP, primarily on the day of surgery. A previous study also assessed the analgesic effect of MP in open pulmonary resection and found a significant pain reduction within the PODs 1-2. However, the patients in this study were given substantially higher doses of MP (25 mg/kg), underwent pulmonary resection by thoracotomy and received postoperative epidural analgesia, which precludes comparison with our findings [11] . The use of an already well-functioning analgesic regime meant that we generally found low median pain scores in both groups in the present study, raising the question of clinical relevance. However, although they were not all statistically significant, median pain scores were lower in the MP group for all activities and time periods and about half of the patients reported severe pain (defined as NRS > _5) [12] at one or more occasions within the first 9 h after surgery. At the same time, we found no increased risk of infection or impaired wound healing, which is consistent with the general conclusions from recent publications on perioperative glucocorticoids and postoperative complications [13] [14] [15] [16] [17] , thereby supporting the use of glucocorticoids for postoperative analgesia after VATS lobectomy. In the present study, we attempted to collect quality data on acute postoperative pain by setting strict criteria for inclusion, which resulted in exclusion of more than 75% of all eligible patients. Nevertheless, we believe that administration of a single highdose of MP may be safe and also have an analgesic effect in the majority of patients like those we excluded from this study. Of special concern may be the significantly increased blood glucose levels in the MP group, which resulted in insulin administration to 6 non-diabetic patients. However, with no registered cases of symptomatic hyperglycaemia, one may question the clinical relevance of this transient side effect. Two previous large-scale studies in cardiac surgery, both of which included patients with diabetes, also found increased blood glucose levels after administration of glucocorticoids but without relation to any clinically relevant adverse events, that would contraindicate their use in patients with or without diabetes [15, 16] . Consistent with results from previous studies [4, 7, 18] , we observed significantly less fatigue and nausea in the MP group on the day of surgery, and although low-point estimates of the latter may indicate little and not severe nausea in both groups, one should also consider the difference in the antiemetic drugs used (Table 5 ). We could not confirm the previously suggested impairment of postoperative sleep quality after MP administration [4] .
In the present study, we used a standard dose of 125 mg MP, which is less than that reported in other procedures [8, 11, 15, 16] but which has been shown to have a pain-reducing effect in arthroplasty [4, 5] and breast surgery [7] . The analgesic effect has previously been suggested in response to high doses of 1-2 mg/kg MP or 0.2-0.4 mg/kg dexamethasone [19] or of 'intermediate' doses of 0.11-0.2 mg/kg dexamethasone [3, 6, 14] . However, with only a few well-defined procedure-specific dose-finding studies available, these findings cannot conclusively be extrapolated to specific procedures. Our findings suggest that the analgesic effect of a single preoperative dose of MP may be of limited duration after VATS lobectomy, thereby raising the question of repeated MP administration in the postoperative period to obtain a sustained pain reducing effect [20] . Therefore, more dose-response and duration studies are needed to elucidate the optimal dose of MP to reach an analgesic effect but at the same time minimizing potential side effects, such as hyperglycaemia. Although this is not fully understood, the pain-reducing effect of glucocorticoids is believed to be mediated through a general attenuation of the systemic inflammatory response [21] . Also, it has been postulated that systemic glucocorticoids may prolong the duration of peripheral nerve blocks [22] , which in our study would mean a potentially prolonged effect of the intraoperatively placed paravertebral nerve block. Nevertheless, additional studies are needed to elucidate the underlying biochemical mechanisms of glucocorticoids to further facilitate their optimal use in reducing acute postoperative pain.
Limitations
This study was limited because the observed pain scores in the placebo group were lower than we expected, thereby introducing the risk of a type II error. Also, our power calculation was based on a mean AUC for pain within a 48-h period, whereas data collection and reporting were done separately from the day of the operation and from PODs 1 and 2, respectively. Furthermore, we had a considerable amount of missing pain data from the day of the operation, which was unequally balanced between the 2 arms. As reported in the results section, many data were missing because of operations performed late in the day. Therefore, we had no pain scores 9 h postoperatively. Assuming that one cannot predict pain based on the time of the operation, these data may be considered as 'missing at random'. We cannot rule out that missing data related to pain during activities may introduce bias if, for example, the lack of pain can be explained by sedation, which was why we performed the 'sensitivity analysis' with multiple imputations of missing data. Another potential bias was that neither caregivers nor investigators were blinded to blood glucose levels, thereby theoretically unmasking group allocation in the few patients with very high glucose levels. Finally, our strict inclusion criteria resulted in a low inclusion rate, which may compromise the generalizability of our findings. The double-blinded, randomized design strengthens the study, and the fact that it was conducted in a single centre means that all patients were operated on by the same surgical technique, were treated under similar perioperative settings, and were followed by just a few investigators, thereby minimizing protocol violations. Also, we assessed pain both at rest and under well-defined activities, which may be relevant in relation to postoperative recovery and the potential development of chronic pain after thoracic surgery [1, 23] . Furthermore, we included follow-up visits at 2 separate points to assess potential complications both in the 'early' post-discharge period (2-3 weeks postoperatively) and in the subsequent period, during which most patients had returned to normal daily activities (3 weeks to 3 months postoperatively).
CONCLUSION
In conclusion, we found that high-dose MP administered preoperatively significantly reduced pain on the day of surgery, both at rest and after mobilization to a sitting position, and reduced nausea and fatigue but had no lasting effects on PODs 1 and 2. Except for transient-increased blood glucose levels on the day of surgery, we found no indication of an increased risk of complications in the MP group.
